July 27, 2018 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin Texas, 78751

Agenda

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings  the day and time of the meeting.

Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

1. Call to order
2. Approval of minutes from April 27, 2018 (vote required)
3. Elect chair (vote required)
4. Bylaws revision (vote required)
5. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the April 27, 2018, meeting
6. New business:
   Public comment on drug classes and therapeutic and clinical drug reviews to be  reviewed for the Medicaid Preferred Drug List (PDL):
   1. Alzheimer’s agents
   2. Antihistamines, minimally sedating
   3. Antihypertensives, sympatholytics
   4. Calcium channel blockers
   5. Cephalosporins and related antibiotics
   6. Fluoroquinolones, oral
   7. Glucocorticoids, oral
   8. Immunosuppressives, oral
   9. Iron, oral
   10. Leukotriene Modifiers
   11. Nonsteroidal anti-inflammatory drugs (NSAIDs)
   12. Ophthalmic antibiotics
   13. Ophthalmic antibiotic-steroid combinations
   14. Ophthalmic for allergic conjunctivitis
   15. Ophthalmic anti-inflammatories
   16. Ophthalmic, glaucoma agents
   17. Otic antibiotics
   18. Otic anti-infectives and anesthetics
   19. Prenatal vitamins
   20. Skeletal muscle relaxants
   21. Steroids, topical high
   22. Steroids, topical low
   23. Steroids, topical medium
   24. Steroids, topical very high
   25. Ulcerative colitis agents

   Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:

   1. Anticoagulants / Eliquis Dose Pack
   2. Antiemetic / Antivertigo Agents / Bonjesta
   3. Chronic Obstructive Pulmonary Disease (COPD) / Lonhala Magnair
   4. Hypoglycemics, incretin mimetics/enhancers / Steglujan
   5. Hypoglycemics, insulin and related agents / Toujeo Max Solostar Pen
   6. Hypoglycemics, SGLT2 / Segluromet
   7. Lipotropics, statins / Zypitamag
   8. Progestational agents / Makena Auto Injector
7. Executive work session
   Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
8. Lunch
9. Announcements of drugs recommended for the Medicaid PDL (vote required)
10. Retrospective DUR:  Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR intervention:
       1. Hypertension management
       2. Major depressive disorder management
    2. Report on recent retrospective DUR intervention outcomes:
       1. Metabolic syndrome
       2. Second-generation antipsychotics in youth
    3. Retrospective DUR proposals:  (vote required)
       1. Opioid prescribing
       2. Second-generation antipsychotics in youth
11. Prospective prior authorization proposals (clinical edits):  Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Carisoprodol Containing Agents - revision
    2. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents - new
12. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Hepatitis C direct-acting antivirals
    2. Immune Globulins
    3. Oral/Rectal NSAIDs
    4. Non-sedating antihistamines
    5. Oral Fluoroquinolones
    6. Rifaximin (Xifaxan®)
    7. Sedative / Hypnotics
    8. Skeletal muscle relaxants
13. Adjourn
14. Next meeting date: October 26, 2018

Contact:  Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.